Wire · operational-macro
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Telix Pharmaceuticals is merging with ITM Isotope Technologies Munich SE to become a vertically integrated radiopharmaceutical leader with expanded isotope production, development, and commercial capabilities. The merger adds ITM's profitable radioisotope manufacturing and late-stage therapeutic candidates, notably ITM-11, to Telix's pipeline, targeting a global market with forecasted $41 billion value by 2034.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 21 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You face a market where consolidation is reshaping radiopharmaceutical supply and pipeline scale. This merger signals a race for control over isotope production and late-stage therapies—if you work in targeted radionuclide therapy, adjust your growth and partnership strategies now.
◆ Coverage
4 sources · first reported 21 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics